glp 1 drugs and rheumatoid arthritis GLP-1 Reduce Symptoms Glucagon-like peptide-1 receptor: mechanisms and

The results provide insights into the benefits and risks of GLP-1RAs and may be useful for informing clinical care and guiding research agendas

Orforglipron is the first oral non-peptide GLP-1 receptor agonist in development for FDA approval to treat weight loss, which could make it more convenient than injectable alternatives 1

Because systemic estrogen affects insulin sensitivity and fat distribution, it can influence the broader metabolic baseline that GLP-1 therapy interacts with

J., Villescaz, C

10 , eaat3392 (2018)

The functional effects of GLP-1 analogues on human eosinophils appear to be linked to their ability to reduce LPS-induced membrane expression of CD69 and CD11b, along with the synthesis of cytokines like IL-4, IL-8, and IL-13 [129]